Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immunogenicity and Safety of Three Tetravalent Formulations of Dengue Vaccine Candidates in Healthy Adults Aged 18 to 45 Years in the US

NCT00617344 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT00617344
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00617344 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immunogenicity and Safety of Three Tetravalent Formulations of Dengue Vaccine Candidates in Healthy Adults Aged 18 to 45 Years in the US
Lead sponsor
Sanofi
Phase
Phase 2
Overall status
Completed
Start date
April 17, 2008
Completion date
February 28, 2010
Enrollment
260 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

dengue fever, dengue hemorrhagic fever, dengue virus